Published in final edited form as:

Bioorg Med Chem. 2008 September 15; 16(18): 8413–8418. doi:10.1016/j.bmc.2008.08.030.

Synthesis and antitumor activity of C-9 epimers of the tetrahydrofuran containing acetogenin 4-deoxyannoreticuin

Feng Wang, Akira Kawamura, and David R. Mootoo*

Department of Chemistry, Hunter College, 695 Park Avenue New York, NY 10021 and The Graduate Center, CUNY, 365 5th Avenue, New York, NY 10016

Abstract

A highly convergent synthesis of mono-tetrahydrofuran (THF) containing acetogenins that is based on the cross metathesis of THF and butenolide alkene precursors, was developed. This methodology was applied to the epimers of the C9 alcohol of 4-deoxyannoreticuin, in an attempt to assign the configuration at this position in the naturally occurring material. Unfortunately, identification of one or the other epimeric structures with the natural product was not possible because of the closeness of the physical data for all three compounds. Both C9 epimeric analogues showed similar cytotoxicity in the low micromolar range, against two human tumor cell lines PC-3 (prostate) and Jurkat (T-cell leukemia). This result contrasts to previous studies on closely related THF acetogenins wherein configurational variation at analogous carbinol centers resulted in a significant effect on antitumor activity.

1. Introduction

The tetrahydrofuran (THF) containing acetogenin family of natural products, of which over 400 have been isolated, are known for their cytotoxic, antitumoral, insecticidal, and immunosuppressive activities.ⁱ Three major subtypes, depending on the number and connectivity of the THF rings have been identified: mono-THF's, adjacently linked bis-THF's, and non-adjacently linked bis-THF's. The cellular target is believed to be the reduced nicotinamide adenine dinucleotide (NADH): ubiquinone oxidoreductase in complex I, a membrane bound protein of the mitochondrial electron transport system.ⁱⁱ Inhibition of electron transfer is believed to disrupt ATP production, which may lead to cell death via a necrosis mechanism. More recent studies suggest that apoptotic pathways could also be involved and may account for the high potency.ⁱⁱⁱ The ubiquinone-linked NADH oxidase that is peculiar to the plasma membrane of cancerous cells has also been suggested as a site of action, and this may explain the activity of the acetogenins against multi-drug resistant tumors.^{iv} The generally high cytotoxicity of these agents presents a challenge to their progress as clinical agents, and in this vein less active analogues might be better suited for lead development. Synthetic studies on the THF acetogenins are relevant to bio-mechanistic investigations^v and have also been valuable for structure determination, in particular with regard to stereochemical assignment.^{vi}

*Corresponding author. Tel.: 212 772 4356; fax.: 212 772 5332; e-mail: E-mail: dmootoo@hunter.cuny.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Against this backdrop we were attracted to 4-deoxyannoreticuin, a relatively simple mono-THF acetogenin with low micromolar level antitumor activity, because the stereochemistry was not completely assigned.^{vii} We were particularly interested in a synthetic plan that would be practical for assigning an unambiguous structure to 4-deoxyannoreticuin and in the longer term would be applicable to other mono-THF acetogenin congeners. The gross structure of 4-deoxyannoreticuin is represented as in **1** or **2** but the configuration at C-9 was not determined (Scheme 1). The relative stereochemistry of the C15–C20 portion was deduced as the *threo-trans-threo* motif on the basis of the known ¹H and ¹³C NMR trends.^{viii} The absolute stereochemistry of the THF core was assigned as 15R, 16R, 19R, 20R because this configuration was determined for the analogous segment in 2,4-*trans*-squamoxinone a co-isolate from the same plant material, and several other mono-THF containing acetogenins.^{vii} It was also assumed that the configuration at C-34 is (*S*) by analogy with all the other acetogenins for which this center has been determined.^{ix} In order to establish the configuration at C-9 we set as synthetic goals the C-9 epimeric structures **1** and **2**, with the plan of matching one or the other to the natural product on the basis of its physical properties. Accordingly, a modular synthesis in which a fixed THF segment **3** could be paired with epimeric-C-9-hydroxy-butenolide components (*R*)-**4** and (*S*)-**4** (or appropriately protected alcohol derivatives), via an olefin cross metathesis (CM), was conceived.^{x,xi}

2. Results and Discussion

The synthesis of the THF segment followed our earlier work on the analog of **3** that contained a hydrocarbon chain with two carbons less.^{xb} Thus, the copper (I) mediated reaction of undecylmagnesium bromide with the known epoxide **5**, followed by desilylation of the product provided diol **3** (Scheme 2)

The epimeric butenolide segments (*R*)-**4** and (*S*)-**4**, originated from the racemic mixture of epoxidized rac-**7** derived from the reaction of methyl dec-9-enoate with mCPBA (Scheme 3). Treatment of rac-**7** under Jacobsen's Hydrolytic Kinetic Resolution (HKR) conditions using (*R,R*)-**8**, or its enantiomer gave either (*R*)-**7** or (*S*)-**7** in 45% and 46% yields, respectively.^{xii} Epoxides (*R*)-**7** and (*S*)-**7** were next converted to the silyl ethers (*R*)-**9** and (*S*)-**9** respectively, via a two-step epoxide opening-alcohol silylation sequence. The ee of these products were deduced to be over 95% by ¹H NMR analysis of their Mosher ester derivatives (supplementary information).^{xiii} Silyl ethers (*R*)-**9** and (*S*)-**9** were individually partnered with aldehyde **10** and forwarded into a known aldol reaction-elimination protocol to give butenolide alkenes (*R*)-**11** and (*S*)-**11** respectively in 39 and 43 % overall yield from (*R*)-**9** and (*S*)-**9**.^{xiv} To compare the use of protected vs deprotected alcohol butenolide partners in the CM and subsequent reactions (*vide infra*), one of the silyl ethers (*S*)-**11**, was converted to the derived alcohol (*S*)-**4**.

The CM and subsequent steps were first evaluated for TBDPS-protected butenolide (*R*)-**11** (Scheme 4). The optimal CM conditions were found to be methylene chloride as the solvent, a 1:2 molar ratio of (*R*)-**11**, 10 mole % Grubbs II catalyst, at room temperature for approximately 20 h. The desired product (*R*)-**12** was obtained in 73% isolated yield based on THF segment **3**. The homodimer of (*R*)-**11** was also isolated in 20% yield together with approximately 15% of unreacted (*R*)-**11**. Selective hydrogenation of the isolated alkene in (*R*)-**12** using RhCl(PPh₃)₃ as a catalyst provided an inseparable 7:1 mixture of the desired hydrogenated product and the completely hydrogenated material in 70% combined yield. Exposure of this mixture to methanolic HCl led to 9R-4-deoxyannoreticuin (**1**) that contained approximately 10% of the corresponding over-reduced product. For the synthesis of 9S-4-deoxyannoreticuin (**2**), the CM reaction was performed with the desilylated butenolide (*S*)-**4** thereby obviating the desilylation step in a more advanced THF-butenolide synthetic intermediate. Accordingly, application of the CM conditions to **3** and (*S*)-**4** gave (*S*)-**13** in 57%

isolated yield based on **3**. Given the difficulty in controlling the $\text{RhCl}(\text{PPh}_3)_3$ catalyzed hydrogenation of (*R*)-**12**, the diimide reduction of (*S*)-**13** was explored and found to be superior, giving 9*S*-4-deoxyannoreticuin (**2**) in 90% yield with no evidence of the over-reduced product.

In the absence of an actual sample of 4-deoxyannoreticuin we attempted to assign the configuration at C-9 in the natural product by comparison of the NMR data for synthetic **1** and **2** with the reported listings for natural 4-deoxyannoreticuin.^{vii} All three sets of data were essentially identical, which corroborated the gross structure assigned to the natural product, but at the same time made assignment of the C-9 configuration impossible. This scenario was not completely surprising given the close similarity, (albeit noticeably different), of the NMR data for the analogous epimers of corossolin, the C-10 regioisomer of 4-deoxyannoreticuin.^{xv,xvi} Similar observations have been made in a recent more rigorous investigation on acetogenin diastereomers that vary with respect to the configuration at remote stereogenic centers.^{vie} Examination of optical rotations were also inconclusive because the values obtained for **1** and **2** were appreciably different from that reported for the natural product, ($[\alpha]_D = +19, +25$ and $+6.8^\circ$ for **1**, **2** and natural 4-deoxyannoreticuin, respectively). Parenthetically, the optical rotations for **1** and **2** were essentially identical to the values observed for the respective C-10 epimers of corossolin.^{xv}

In the case of corossolin^{xv} the cytotoxic activities of the C-10 epimers were significantly different. Therefore in an attempt to identify **1** or **2** with the natural based on differences in biological activity, the activity of **1** and **2** against PC-3 (human prostate) was evaluated with the expectation that one or the other would more closely match the reported data for the natural product. The GI_{50} values for **1** and **2** were found to be approximately 15 and 10 $\mu\text{g/mL}$ in a 3 day MTS assay. The ED_{50} reported for the natural sample is 2.7 $\mu\text{g/mL}$ in a 7 day MTT assay.^{vii} Thus, preliminary biological evaluation was also not structurally insightful. Epimers **1** and **2** also showed similar activity against Jurkat cells (human T-cell leukemia), with GI_{50} values in the range of 5–10 $\mu\text{g/mL}$. These data suggest that the notion that a change in the configuration at such remote carbinol centers leads to significant difference in cytotoxic activity may hold only for certain cell lines and is not general.

3. Conclusion

In conclusion we have developed a highly convergent synthesis for mono-THF containing acetogenins that is based on the CM coupling of THF and butenolide components. This methodology was applied to the epimeric analogues of the natural product 4-deoxyannoreticuin, in an attempt to resolve the unassigned configuration at C-9. Unfortunately, identification of one or the other epimeric structures with the natural product was not possible because of the closeness of the physical data for all three compounds, illustrating the limitation of this strategy for the assignment of stereochemistry at remote stereogenic centers. In contrast to observations made for closely related THF acetogenins, the cytotoxicity of the epimeric analogues of 4-deoxyannoreticuin were found to be very similar.

4. Experimental

4.1 General

Solvents were purified by standard procedures or used from commercial sources as appropriate. Petroleum ether refers to the fraction of petroleum ether boiling between 40 and 60 $^\circ\text{C}$. Unless otherwise stated thin layer chromatography (TLC) was done on 0.25 mm thick precoated silica gel 60 (HF-254, Whatman) aluminium sheets and flash column chromatography (FCC) was performed using Kieselgel 60 (32–63 mesh, Scientific Adsorbents). Elution for FCC usually employed a stepwise solvent polarity gradient, correlated with TLC mobility. Chromatograms were observed under UV (short and long wavelength) light, and/or were visualized by heating

plates that were dipped in a solution of ammonium (VI) molybdate tetrahydrate (12.5 g) and cerium (IV) sulfate tetrahydrate (5.0 g) in 10% aqueous sulphuric acid (500 mL). Optical rotations ($[\alpha]_D$) were recorded using a Rudolph Autopol III polarimeter which has a thermally jacketed 10 cm cell (path length of 1 dm) and are given in units of 10^{-1} degcm²g at 589 nm (sodium D-line). NMR spectra were recorded using either Varian Unity Plus 500 or Bruker Ultra Shield instruments (¹H and ¹³C; 500 and 125 MHz respectively). Spectra were recorded in CDCl₃ solutions with residual CHCl₃ as internal standard (δ_H 7.27 and δ_C 77.0 ppm). Chemical shifts are quoted in ppm relative to tetramethylsilane (δ_H 0.00) and coupling constants (J) are given in Hertz (Hz). First order approximations are employed throughout. High-resolution mass spectrometry was performed on an Ultima Micromass Q-ToF instrument at the Mass Spectrometry Laboratory of the University of Illinois, Urbana-Champaign.

4.2. (2R, 5R, 1'R, 1''R)-2-[1'-Hydroxy-2'-propenyl]-5-[1''-hydroxytridecyl]-tetrahydrofuran (3)

In a 50 mL round-bottom flask equipped with magnetic stirring bar, were placed CuBr (36.3 mg, 0.253 mmol) and anhydrous THF (10 mL). Pre-prepared, C₁₁H₂₃MgBr (11.5 mL, ca 0.4 M in THF) was added dropwise at 0 °C, and then epoxide **5^{xb}** (120 mg, 0.422 mmol) was introduced. The reaction was stirred at 0 °C for 3 h, then poured into ice cold saturated aqueous NH₄Cl, and extracted with ether. The organic phase was washed with brine, dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by FCC (2–5% EtOAc:petroleum ether) to give the derived alcohol (160 mg, 86%): R_f = 0.45 (5% EtOAc: petroleum ether); ¹H NMR (CDCl₃) δ 5.81 (m, 1H), 5.24–5.28 (dd, 2H, J = 17.1 Hz, 10.6 Hz), 4.10 (t, 1H), 3.88–3.89 (q, 1H), 3.75–3.76 (q, 1H), 3.35 (m, 1H), 2.31 (d, 1H, J = 4.1 Hz), 1.86–1.89 (m, 2H), 1.52–1.70 (m, 2H), 1.36 (m, 1H), 1.36–1.38 (m, 2H), 1.23 (s, br, 19H), 0.88 (s, br, 9H), 0.85 (t, J = 6.7 Hz, 3H), 0.05 (s, 3H), 0.03 (s, 3H); ¹³C NMR (CDCl₃) δ 137.6, 115.7, 82.7, 82.4, 76.0, 74.0, 33.6, 31.9, 29.7 (two signals), 29.6 (three signals), 29.3, 28.4, 27.8, 25.8, 25.6, 22.7, 18.3, 14.1, 1.0, –4.6, –4.8; HRMS (FAB) calcd for C₂₆H₅₃O₃Si (M + H⁺) 441.3764, found 441.3744.

To a solution of the product from the previous step (64 mg, 0.145 mmol) in THF (10 mL) was added Bu₄NF (1.45 mL, 1M in THF) at 0 °C. The reaction was stirred at rt until TLC indicated complete disappearance of the starting material, at which time the mixture was diluted with water and extracted with EtOAc. The organic phase was dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by FCC to give **3** (40 mg, 85%): white powder; R_f = 0.3 (25% EtOAc: petroleum ether); ¹H NMR (CDCl₃) δ 5.78 (m, 1H), 5.18–5.36 (dd, 2H, J = 17.5, 10.5 Hz), 3.93 (m, 1H), 3.80–3.88 (m, 2H), 3.39 (m, 1H), 2.45 (b, 1H), 2.25 (b, 1H), 1.94–1.98 (m, 2H), 1.68–1.73 (m, 2H), 1.40–1.41 (m, 1H), 1.29–1.38 (m, 3H), 1.24 (s, br, 18H), 0.86 (t, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 136.7, 117.1, 82.9, 82.2, 75.5, 74.0, 33.6, 31.9, 29.7 (three signals), 29.6 (three signals), 29.3, 28.5, 28.4, 25.6, 22.7, 14.1; HRMS (FAB) calcd for C₂₀H₃₈O₃Na (M + Na⁺) 349.2719, found 349.2708.

4.3. Methyl 8-(oxiran-2-yl)octanoate (7)

To a solution of methyl dec-9-enoate (1.40 g, 7.60 mmol) in CH₂Cl₂ (25 mL) was added *m*CPBA (4.26 g, 19 mmol, 77% purity) at room temperature. The mixture was stirred for 1h and quenched by adding saturated aqueous NaHCO₃ and saturated aqueous Na₂S₂O₃, and extracted with EtOAc. The organic phase was dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by FCC to give **7** (1.31 g, 86.4%) as a yellow oil; R_f = 0.70 (10% EtOAc: petroleum ether); ¹H NMR (CDCl₃) δ 3.69 (s, 3H), 2.92 (m, 1H), 2.75–2.77 (m, 1H), 2.47–2.48 (m, 1H), 2.32 (t, J = 7.5 Hz, 2H), 1.60–1.62 (m, 2H), 1.34–1.55 (m, 10H); ¹³C NMR (CDCl₃) δ 174.2, 52.3, 51.4, 47.1, 34.1, 32.4, 29.2, 29.1, 29.0, 25.9, 24.9.

4.4. (R)- Methyl 8-(oxiran-2-yl)octanoate [(R)-7]

A solution of (*R/S*)-**7** (1.83 g, 9.17 mmol) in DME (10 mL) was treated with (*R,R*)-salen-Co (OAc) (182 mg, 0.275 mmol) and distilled water (0.091 mL, 5.06 mmol). The mixture was stirred at room temperature for 72 h, then purified by FCC to give (*R*)-**7** (677 mg, 37%) and the derived diol (765 mg, 38%). The TLC and NMR data for (*R*)-**7** was as listed for (*R/S*)-**7**.

4.5. (S)-Methyl 8-(oxiran-2-yl)octanoate [(S)-7]

(*S*)-**7** (4.2 g, 46%) was obtained from (*R/S*)-**7** (9.2 g, 46 mmol) using (*S,S*)-**8**, following the procedure described for (*R*)-**7**. The TLC and NMR data for (*S*)-**7** was as listed for (*R/S*)-**7**.

4.6. (S)-methyl 9-tert-butyldiphenylsilyloxytetradec-13-enoate [(S)-9]

To a suspension of CuBr (258 mg, 1.8 mmol) in THF (15 mL) at 0 °C was added 3-butenylmagnesium bromide (18 mL, 0.5 M in THF, 9.0 mmol) over 5 min. A solution of (*S*)-**7** (600 mg, 3.00 mmol) in anhydrous THF (3 mL) was then introduced, dropwise over 5 min. The reaction was stirred at 0 °C for 10 min at which time saturated aqueous NH₄Cl was added and the mixture extracted with ether. The organic phase was washed with brine, dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by FCC to give the derived alcohol: R_f = 0.50 (20% EtOAc: petroleum ether).

A solution of the product from the previous step (358 mg, 1.4 mmol), TBDPSCl (769 mg, 2.8 mmol) and imidazole (477 mg, 7.00 mmol) in anhydrous CH₂Cl₂ (20 mL) was stirred under nitrogen at room temperature for 2 h. The mixture was quenched with brine and extracted with ether (3 × 50 mL). The organic phase was dried (Na₂SO₄) filtered, and evaporated under reduced pressure. The residue was purified by FCC to afford **9** (600 mg, 87%) as a pale yellow oil. R_f = 0.50 (5% EtOAc: petroleum ether); ¹H NMR (CDCl₃) δ 7.69–7.70 (m, 4H), 7.37–7.44 (m, 6H), 5.71–5.74 (m, 1H), 4.91–4.96 (m, 2H), 3.75 (m, 1H), 3.70 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 1.92–1.93 (m, 2H), 1.59–1.60 (m, 2H), 1.40–1.45 (m, 6H), 1.14–1.23 (m, 8H), 1.08 (s, 9H); ¹³C NMR (CDCl₃) δ 174.5, 139.2, 136.2, 135.1, 135.0, 129.6, 127.6, 114.5, 77.0, 73.3, 51.6, 36.5, 36.0, 34.3, 34.0, 29.7, 29.3 (two signals), 27.3, 25.1, 25.0, 24.4, 19.6.

4.7. (R)-methyl 9-tert-butyldiphenylsilyloxytetradec-13-enoate [(R)-9]

(*R*)-**9** (600 mg, 75%) was obtained from (*R*)-**7** (324 mg, 1.62 mmol) following the two step reaction sequence described for (*S*)-**9**. The TLC and NMR data for (*R*)-**9** was as listed for (*S*)-**9**.

4.8. Butenolide (R)-11

To a solution of diisopropylamine (1.2 mL, 8.5 mmol) in anhydrous THF (15 mL) at –78 °C, was added BuLi (2.4 mL, 2.5 M in hexane, 6 mmol). The mixture was warmed to 0 °C and stirred at this temperature for 10 min, then cooled to –78 °C, at which time a solution of (*R*)-**9** (600 mg, 1.21 mmol) in anhydrous THF (6 mL) was added. The reaction mixture was stirred at –78 °C for 1 h and a solution of aldehyde **10**^{Xiv} (574 mg, 3.63 mmol) in anhydrous THF (6 mL) was slowly introduced. After 30 min, the reaction was quenched with saturated aqueous NH₄Cl and extracted with ether. The organic extract was dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by FCC to afford the aldol product as clear syrup (400 mg, 70% based on consumed (*R*)-**9**).

To the solution of product from the previous step (400 mg, 0.613 mmol) in a mixture of MeOH (10 mL) and 2-propanol (1 mL) was added TsOH (12 mg, 0.06 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 20 h, then concentrated under reduced pressure. The residue was purified by FCC to afford the derived lactone as a yellow oil (227 mg, 69%).

To a solution of the material from the previous step (227 mg, 0.42 mmol) in CH_2Cl_2 (10 mL) was added Et_3N (0.3 mL, 2.1 mmol) and MsCl (0.07 mL, 0.84 mmol) at 0 °C. After stirring at room temperature for 14 h, the reaction was diluted with saturated aqueous NH_4Cl and extracted with ether. The organic phase was dried (Na_2SO_4) and concentrated under reduced pressure. The residue was purified by FCC to afford (**R**)-**11** (176 mg, 81%) as a clear oil. R_f = 0.75 (15% EtOAc: petroleum ether); ^1H NMR (CDCl_3) δ 7.66–7.68 (m, 4H), 7.35–7.41 (m, 6H), 6.94 (d, J = 1.5 Hz, 1H), 5.69–5.72 (m, 1H), 4.97–4.99 (m, 1H), 4.88–4.94 (m, 2H), 3.70–3.74 (m, 1H), 2.20–2.24 (m, 2H), 1.90–1.91 (m, 2H), 1.38–1.47 (m, 11H), 1.14–1.1.23 (m, 6H), 1.05 (s, 9H); ^{13}C NMR (CDCl_3) δ 173.8, 148.8, 138.9, 135.9, 134.8, 134.7, 134.3, 129.4 (two signals), 127.4, 114.3, 73.1, 36.3, 35.8, 33.8, 29.3, 29.1, 27.3, 27.1, 25.1, 24.7, 24.2, 19.4, 19.2; HRMS (FAB) calcd for $\text{C}_{33}\text{H}_{47}\text{O}_3\text{Si}$ ($\text{M} + \text{H}^+$) 519.3294, found 519.3282.

4.9. Butenolide (S)-11

Colorless oil; R_f = 0.70 (15% EtOAc: petroleum ether); ^1H NMR (CDCl_3) δ 7.69–7.70 (m, 4H), 7.37–7.45 (m, 6H), 6.96 (d, J = 1.4 Hz, 1H), 5.71–5.76 (m, 1H), 5.00–5.01 (m, 1H), 4.91–4.96 (m, 2H), 3.74–3.76 (m, 1H), 2.23–2.26 (t, J = 8.1 Hz, 2H), 1.92–1.93 (m, 2H), 1.25–1.49 (m, 11H), 1.16–1.23 (m, 6H), 1.08 (s, 9H); ^{13}C NMR (CDCl_3) δ 173.8, 148.7, 138.9, 135.9, 134.8, 134.7, 134.4, 129.4, 127.4, 114.3, 73.1, 36.3, 35.8, 33.8, 29.3, 29.1, 27.3, 27.1, 25.1, 24.7, 24.2, 19.4, 19.2; HRMS (FAB) calcd for $\text{C}_{33}\text{H}_{47}\text{O}_3\text{Si}$ ($\text{M} + \text{H}^+$) 519.3294, found 519.3293.

4.10. Butenolide (S)-4

5% AcCl in MeOH (2.1 mL) was added at room temperature to a solution of (**S**)-**11** in CH_2Cl_2 (5 mL). The mixture was stirred for 16 h, then diluted with CH_2Cl_2 and washed with saturated aqueous NaHCO_3 . The organic phase was dried (Na_2SO_4) and concentrated under reduced pressure. FCC of the residue afforded (**S**)-**4** (50 mg, 82%); clear oil; R_f = 0.45 (30% EtOAc: petroleum ether); ^1H NMR (CDCl_3) δ 7.00 (s, 1H), 5.81–5.86 (m, 1H), 4.97–5.06 (m, 3H), 3.61–3.62 (m, 1H), 2.27–2.31 (m, 2H), 2.02–2.11 (m, 2H), 1.37–1.58 (m, 18H); ^{13}C NMR (CDCl_3) δ 173.8, 148.8, 138.7, 134.3, 114.6, 71.8, 37.4, 36.9, 33.7, 29.3, 29.1, 27.4, 25.5, 24.9, 19.2; HRMS (FAB) calcd for $\text{C}_{17}\text{H}_{29}\text{O}_3$ ($\text{M} + \text{H}^+$) 281.2117, found 281.2111.

4.11. THF-butenolide (R)-12

Grubb's II catalyst (6 mg, 0.007 mmol) in CH_2Cl_2 (1 mL) was injected, at rt, into a degassed solution of alcohol **3** (23 mg, 0.07 mmol) and (**R**)-**11** (74 mg, 0.14 mmol), in CH_2Cl_2 (2 mL). The reaction was stirred for 20 h at rt, then quenched by addition of DMSO (50 μL) and concentrated *in vacuo*. FCC of the residue afforded (**R**)-**12** (42 mg, 73% based on **3**), recovered (**R**)-**11** (ca 15%) and the homodimer (**R**)-**11** (ca 20 %). For (**R**)-**12**: clear oil; R_f = 0.50 (30% EtOAc: petroleum ether); ^1H NMR (CDCl_3) δ 7.65–7.67 (m, 4H), 7.34–7.42 (m, 6H), 6.94 (s, 1H), 5.65–5.68 (m, 1H), 5.32–5.34 (m, 1H), 4.97–4.99 (m, 1H), 3.81–3.85 (m, 3H), 3.70–3.73 (m, 1H), 3.41 (m, 1H), 2.43–2.44 (m, 1H), 2.20–2.21 (m, 3H), 1.88–1.89 (m, 4H), 1.20–1.47 (m, 41H), 1.04 (s, 9H), 0.89 (t, J = 3.2 Hz, 3H); ^{13}C NMR (CDCl_3) δ 173.8, 149.5, 149.3, 149.1, 148.7, 135.9, 134.7, 134.5, 134.3, 129.4, 128.3, 127.4, 123.1, 123.0, 122.7, 82.7, 82.6, 75.6, 74.0, 73.0, 33.6, 31.9, 29.7 (three signals), 29.6 (three signals), 29.3 (two signals), 29.1, 28.4 (two signals), 27.3, 27.1, 25.1, 22.7, 19.2, 14.1; HRMS calcd for $\text{C}_{51}\text{H}_{80}\text{O}_6\text{SiNa}$ ($\text{M} + \text{Na}^+$) 839.5622, found, 839.5613.

4.12. THF-butenolide (S)-13

Grubb's II catalyst (9.3 mg, 0.01 mmol) in CH_2Cl_2 (1 mL) was injected, at rt, into a degassed solution of alcohol **3** (36 mg, 0.11 mmol), and (**S**)-**4** (50 mg, 0.178 mmol), in CH_2Cl_2 (2 mL). The reaction was stirred for 20 h at rt, then quenched by addition of DMSO (50 μL) and concentrated *in vacuo*. FCC of the residue provided (**S**)-**13** (36 mg, 57% based on **3**), and the homodimer of (**S**)-**4** (ca 27%). For (**S**)-**13**: clear oil; R_f = 0.50 (80% EtOAc: petroleum

ether); ^1H NMR (CDCl_3) δ 7.01 (s, 1H), 5.76–5.82 (m, 1H), 5.41–5.46 (m, 1H), 5.02–5.03 (m, 1H), 3.85–3.92 (m, 3H), 3.61 (s, br, 1H), 3.42–3.44 (m, 1H), 2.29 (t, J = 7.5 Hz, 2H), 2.10 (m, 2H), 1.97–2.01 (m, 2H), 1.28–1.70 (m, 44H), 0.90 (t, J = 6.6 Hz, 3H); ^{13}C NMR (CDCl_3) δ 173.9, 148.9, 134.3, 128.6, 82.8, 82.5, 76.8, 76.7, 75.5, 74.0, 71.7, 37.4, 36.9, 32.3, 31.9, 29.7, (five signals), 29.6, 29.4, 29.3, 29.2, 27.4, 25.6, 25.5, 25.2, 22.7, 19.2, 14.2; HRMS (FAB) calcd for $\text{C}_{35}\text{H}_{63}\text{O}_6$ ($\text{M} + \text{H}^+$) 579.4614, found 579.4625.

4.13. (9R)-4-deoxyannoreticuin (1)

Chlorotris(triphenylphosphine)-rhodium (I) (7.1 mg, 0.0077 mmol) was added to a degassed solution of (**R**)-**12** (23 mg, 0.028 μmol) in a mixture of benzene-EtOH (2 mL, 50% v/v). The mixture was stirred under an atmosphere of hydrogen for 12 h, at which time the solvent was removed under reduced pressure. FCC of the residue gave an inseparable mixture of the 13,14-dihydro- and tetrahydro derivatives of (**R**)-**12** (16 mg, 70%); R_f = 0.50 (30% EtOAc: petroleum ether).

A mixture of 5% AcCl in MeOH (0.5 mL) was added at room temperature to a solution of the material obtained in the previous step (10 mg, 12.2 μmol) in CH_2Cl_2 (1 mL). The mixture was stirred at this temperature for 3 h, diluted with CH_2Cl_2 , and washed with a saturated aqueous NaHCO_3 . The organic layer was dried (Na_2SO_4), filtered, and concentrated under reduced pressure. FCC of the residue afforded a mixture of **1** and the completely hydrogenated product (7.2 mg, 72%) in an approximate 7:1 ratio; R_f = 0.35 (60% EtOAc: petroleum ether); Repeated FCC provided a sample of **1** that contained less than 10% of the completely reduced material as a white waxy solid; $[\alpha]_D^{25} +19$ (c 2.00, CH_2Cl_2); ^1H NMR (CDCl_3) δ 6.96 (s, 1H), 4.96–4.98 (m, 1H), 3.76–3.80 (m, 2H), 3.56 (s, br, 1H), 3.36–3.41 (m, 2H), 2.25–2.27 (m, 4H, CH_2 , 2xOH, D_2O ex.), 1.96–1.97 (m, 2H), 1.24–1.52 (m, 48H), 0.87 (t, J = 6.8 Hz, 3H); ^{13}C NMR (CDCl_3) δ 173.8, 148.9, 134.3, 82.7, 77.4, 74.0 (two signals), 71.9, 37.4, 33.5, 33.4, 31.9, 29.7 (three signals), 29.6 (three signals), 29.3, 29.1, 28.7, 27.3, 25.6 (three signals), 25.5, 25.2, 22.7, 19.2, 14.1; HRMS (FAB) calcd for $\text{C}_{35}\text{H}_{65}\text{O}_6$ ($\text{M} + \text{H}$) 581.4781, found 581.4794.

4.14. (9S)-4-deoxyannoreticuin (2)

A solution of sodium acetate (280 mg, 3.41 mmol) in water (5 mL) was added via a syringe pump, over 4 h, to a mixture of (**S**)-**13** (24 mg, 0.041 mmol), p-toluenesulfonyl hydrazide (511 mg, 2.74 mmol) and DME (4 mL) at reflux. After cooling to rt, the reaction mixture was poured into water and extracted with EtOAc. The combined organic extract was washed with 2M HCl, water and brine, dried (Na_2SO_4), filtered, concentrated under reduced pressure and purified by FCC to give **2** as a white waxy solid (21.5 mg, 90%). R_f = 0.50 (80% EtOAc: petroleum ether); $[\alpha]_D^{25} +25$ (c 4.00, CH_2Cl_2); ^1H NMR (CDCl_3) δ 6.96 (s, 1H), 4.95–4.99 (m, 1H), 3.76–3.80 (m, 2H), 3.56 (s, br, 1H), 3.36–3.40 (m, 2H), 2.23–2.24 (m, 2H), 1.95–1.96 (m, 2H), 1.66 (m, 2H), 1.23–1.53 (m, 48H), 0.86 (t, J = 6.8 Hz, 3H); ^{13}C NMR (CDCl_3) δ 173.8, 148.9, 134.3, 82.7, 82.6, 77.4, 74.0, 71.9, 37.4, 33.5, 33.4, 31.9, 29.7, 29.6, 29.3, 29.1, 28.7, 27.4, 25.6, 25.5, (two signals), 22.7, 19.2, 14.1; HRMS calcd for $\text{C}_{35}\text{H}_{65}\text{O}_6$ ($\text{M} + \text{H}$) 581.4781, found 581.4789.

4.15. Cytotoxicity Assay

Cells were cultured in RPMI medium supplemented with 10% fetal bovine serum and penicillin-streptomycin-fungizone mixture (100 units/mL, 100 $\mu\text{g}/\text{mL}$ and 0.25 $\mu\text{g}/\text{mL}$ respectively) and maintained in a 37 °C humidified 5% CO_2 incubator. On the day before the drug treatment, cells were plated onto each well of 96-well plate at 2,000 cells/well (200 μl of the medium per well). After 24 hours, cells were treated with different concentrations of compounds and incubated for 72 hours. After the incubation, cell growth was evaluated using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). UV absorption (490

nm) of each well was quantified by SpectraMax Plus 384 microplate reader (Molecular Devices). The data is provided as supplementary information.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

This investigation was supported by grant R01 GM57865 from the National Institutes of Health (NIH). "Research Centers in Minority Institutions" award RR-03037 from the National Center for Research Resources of the NIH, which supports the infrastructure and instrumentation of the Chemistry Department at Hunter College is also acknowledged.

References and notes

- i. (a) Zeng L, Ye Q, Oberlies NH, Shi G, Gu ZM; He K, McLaughlin JL. *Nat. Prod. Rep* 1996;13:275–306. [PubMed: 8760865] (b) Alali FQ, Liu XX, McLaughlin JL. *J. Nat. Prod* 1999;62:504–540. [PubMed: 10096871] (c) Bermejo A, Figadere B, Zafra-Polo M-C, Barrachina I, Estornell E, Cortes D. *Nat. Prod. Rep* 2005;22:269–303. [PubMed: 15806200]
- ii. (a) Lewis MA, Arnason JT, Philogene BJR, Rupprecht JK, McLaughlin JL. *Pesticide Biochem. Physiol* 1993;45:15–23. (b) Londershausen M, Leicht W, Lieb F, Moeshler H, Weiss H. *Pesticide Sci* 1991;33:427–438.
- iii. (a) Wolvetang EJ, Johnson KL, Krauser K, Ralph SJ, Linnane AW. *FEBS Lett* 1994;339:40–44. [PubMed: 8313978] (b) Chiu HF, Chih TT, Hsian YM; Tseng CH, Wu MJ, Wu YC. *Biochem Pharmacol* 2003;65:319–327. [PubMed: 12527325] (c) Yuan SS, Chang HL, Chen HW, Kuo FC, Liaw CC, Su JH, Wu YC. *Life Sci* 2006;78:869–874. [PubMed: 16154156]
- iv. Morré DJ, Cabo RD, Farley C, Oberlies NH, McLaughlin JL. *Life Sci* 1995;56:343–348. [PubMed: 7837933]
- v. For recent examples: (a) Takada M, Kuwabara K, Nakato H, Tanaka A, Iwamura H, Miyoshi H. *Biochim Biophys Acta* 2000;1460:302–310. [PubMed: 11106771] (b) Arndt S, Emde U, Baurle S, Friedrich T, Grubert L, Koert U. *Chem. Eur. J* 2001;7:993–1005. (c) Duval RA, Lewin G, Peris E, Chahboune N, Garofano A, Dröse S, Cortes D, Brandt U, Hocquemiller R. *Biochemistry* 2006;45:2721–2728. [PubMed: 16489765]
- vi. Selected examples: (a) Hoyer TR, Zhuang ZP. *J. Org. Chem* 1988;53:5578–5580. (b) Takahashi S, Maeda K, Hirota S, Nakata T. *Org Lett* 1999;1:2025–2028. [PubMed: 10905863] (c) Marshall JA, Piettre A, Paige MA, Valeriote F. *J. Org. Chem* 2003;68:1780–1785. [PubMed: 12608791] (d) Narayan RS, Borhan B. *J. Org. Chem* 2006;71:1416–1429. [PubMed: 16468789] (e) Curran DP, Zhang Q, Lu H, Gudipati V. *J. Am. Chem. Soc* 2006;128:9943–9956. [PubMed: 16866554]
- vii. Hopp DC, Alali FQ, Gu ZM, McLaughlin JL. *Phytochemistry* 1998;47:803–809. [PubMed: 9542173]
- viii. Hopp DC, Zeng L, Gu Z-M, Kozlowski JF, McLaughlin J. L. *J. Nat. Prod* 1997;60:581–586.
- ix. Zeng L, Ye Q, Oberlies NH, Shi G, Gu Z-M, He K, McLaughlin JL. *Nat. Prod. Rep* 1996;13:275–306. [PubMed: 8760865]
- x. For related examples of olefin metathesis strategies in THF acetogenin synthesis: (a) Evans PA, Cui J, Gharpure SJ, Polosukhin A, Zhang H-R. *J. Am. Chem. Soc* 2003;125:14702–14703. [PubMed: 14640634] (b) Zhu L, Mootoo DR. *J. Org. Chem* 2004;69:3154–3157. [PubMed: 15104456] (c) Das S, Li L-S, Abraham S, Chen Z, Sinha SC. *J. Org. Chem* 2005;70:5922–5931. [PubMed: 16018687] (d) Crimmins MT, Zhang Y, Diaz FA. *Org. Lett* 2006;8:2369–2372. [PubMed: 16706528] (e) Hoyer TR, Eklov BM, Jeon J, Khorroosi M. *Org. Lett* 2006;8:3383–3386. [PubMed: 16836411] (f) Marshall JA, Sabatini JJ. *Org. Lett* 2006;8:3557–3560. [PubMed: 16869659] (g) Takahashi S, Hongo Y, Ogawa N, Koshino H, Nakata T. *J. Org. Chem* 2006;71:6305–6308. [PubMed: 16872228] (h) Quinn KJ, Smith AG, Cammarano CM. *Tetrahedron* 2007;63:4881–4886.
- xi. For application of ring closing metathesis to the cyclic ether residues in the acetogenins: (a) ref. ^{8d}. (b) Prestat G, Baylon C, Heck MP, Grasa GA, Nolan SP, Mioskowski C. *J. Org. Chem* 2004;69:5770–5773. [PubMed: 15307756]
- xii. Tokunaga M, Larrow JF, Kakiuchi F, Jacobsen EN. *Science* 1997;277:936–938. [PubMed: 9252321]

- xiii. (a) Rieser MJ, Hui YH, Rupprecht JK, Kozlowski JF, Wood KV, McLaughlin JL, Hanson PR, Zhuang Z, Hoye TR. *J. Am. Chem.Soc* 1992;114:10203–10213. For application of Mosher ester analysis of a remote carbinol center: (b) Ye Q, Alfonso D, Evert D, McLaughlin JL. *Bioorg. Med. Chem* 1996;4:537–545. [PubMed: 8735841].
- xiv. (a) Sinha SC, Sinha A, Sinha SC, Keinan E. *J. Am. Chem.Soc* 1997;119:12014–12015. (b) Avedissian H, Sinha SC, Yazbak A, Sinha A, Neogi P, Sinha SC; Keinan E. *J. Org. Chem* 2000;65:6035–6051. [PubMed: 10987938]
- xv. Yu Q, Yao Z-J, Chen X-G, Wu Y-L. *J. Org. Chem* 1999;64:2440–2445.
- xvi. Makabe H, Tanimoto H, Tanaka A, Oritani T. *Heterocycles* 1996;43:2229–2248.

Scheme 1.
Retrosynthesis for 4-deoxyannoreticuin

Scheme 2.
Synthesis of THF segment

Scheme 4.
Cross metathesis and final products